Baicalin and wogonoside are two of the most abundant flavonoid glycosides in the root of Scutellaria baicalensis Georgi, which is a widely used peroral herbal medicine with anticancer, antiviral, antibacterial and anti-inflammatory properties. In the present study, the effects of intestinal microecology on the metabolism and pharmacokinetics of orally administered baicalin and wogonoside were investigated by UPLC-QTOF/MS measurement of the difference in metabolites between normal and antibiotic-pretreated rats. In the antibiotic-pretreated rats, the plasma concentration-time profile and pharmacokinetic parameters of the two flavonoid glycosides and their relevant aglycone forms were significantly changed compared with those in normal rats. Further, hydrolysis and glucuronidated metabolites were not detected in the cecum contents and urine samples from antibiotic-pretreated rats. These results suggested that intestinal microbiota may play a key role in the pharmacokinetics and metabolism of peroral baicalin and wogonoside. According to our findings, it is recommended that the root of S. baicalensis should not be co-administered with antibiotics in clinical use.
The root of Scutellaria baicalensis Georgi (Labiatae), also known as Huangqin in Chinese, is an ancient herbal medicine that is commonly used in Asian countries. It has been documented with multiple therapeutic properties such as anticancer, antiviral, antibacterial and anti-inflammatory effects [1] , and usually prescribed as a diuretic, laxative, febrifuge, and antipyretic, and for hemoptysis, bloody stool, and nasal hemorrhage when prescribed in a compound recipe [2] . Additionally, Huangqin is also a functional food component in Chinese medicated diet for health promotion and disease prevention [3] . The abundant flavonoids within Huangqin primarily account for these observed biological activities. More than 40 flavonoid derivatives have been identified from the root of S. baicalensis [4] , among which baicalin and wogonoside are the two most abundant [5] . Baicalin is listed in the quality control index of Pharmacopoeia of China [3] .
Because TCMs are most often orally administered as decoctions, the TCM constituents are metabolized in the gastrointestinal tract by intestinal bacteria, and the biological activities of these compounds will be affected by the condition of the intestinal microbiota [6] . According to our previous report, baicalin and wogonoside are metabolized into their aglycons, baicalein and wogonin by human intestinal microbiota, and these metabolites possess higher anticomplementary and antimicrobial activity than their parent compounds [7] . Furthermore, baicalein and wogonin are more preferred forms for in vivo absorption than baicalin and wogonoside, respectively [8, 9] . Under in vivo physiological conditions, baicalein can be resynthesized to baicalin or transformed to its glucuronide forms such as baicalein-6glucuronide [10] . Studies show that antibiotics treatment can significantly attenuate the anti-inflammatory effect of orally administered baicalin in mice, indicating the influence of intestinal microflora on the in vivo process of baicalin and its antiinflammatory effect [11] . Thus, the production of aglycones by hydrolysis of the flavonoid glycosides in the intestine is a critical factor for determining the absorption and metabolic transformation of flavonoid glycosides. In addition, pharmacokinetic studies of flavonoid glycosides in S. baicalensis indicated that baicalin and wogonoside have double-site absorption kinetics in rats because of enteric and enterohepatic circulation after oral administration [12, 13] . Although a previous report has found that the intestinal microbiota play a key role in the pharmacokinetics of baicalin [14] , the role of intestinal microbiota in the metabolic process of flavonoid glycosides and the contents of metabolites have not been extensively investigated in vivo. In this study, the effects of intestinal microecology on the pharmacokinetics of oral baicalin and wogonoside were assessed by UPLC-MS/MS, and the difference in metabolites in vivo between normal and antibioticpretreated rats were analyzed by UPLC-QTOF/MS. From this study, a critical role of intestinal microbiota in the oral pharmacokinetics and metabolism of baicalin and wogonoside were clearly demonstrated. Two metabolites were found in the cecal contents of normal rats receiving oral baicalin administration. The constituents were well separated using the developed UPLC method. M1 was detected based on the same retention time as an authentic standard and thus identified unequivocally as baicalein. M2 was identified as oroxylin A by comparison with a reference standard.
Three distinct metabolites and baicalin were detected in the urine samples of normal rats after oral administration of baicalin compared with the blank urine. These four compounds were numbered M1-M4 by their retention time. M2 showed a protonated molecular ion [M+H] + at m/z 447 and a retention time of 8.31 min. Based on these, M2 was identified as baicalin. Metabolite M1 was detected as the deprotonated molecular ion [M+H] + at m/z 623 with a retention time of 7.13 min, which is 176 Da heavier than the protonated ion of baicalin. This indicated the metabolite might be the glucuronide conjunction product of baicalin, baicalein-6-Oglucuronide-7-O-glucuronide. M1 disappeared after glucuronidase hydrolysis of the urine samples. Considering that glucuronidation on C-5 of the A ring in the flavone structure is difficult, M1 could be baicalein-6-O-glucuronide-7-O-glucuronide. Metabolite M3 exhibited a [M+H] + ion at m/z 461 with a retention time of 9.43 min, which was, thereafter, confirmed as oroxyloside by comparing its retention time and MS with a reference sample. Metabolite M4 showed an [M+H] + ion at m/z 447 with a retention time of 9.82 min and was an isomer of baicalin. Because of the chemical inertness of the 5-hydroxyl group in baicalein, the conjugation point of the glucuronyl group in the structure of M4 should be on the 6hydroxyl group of baicalein. Thus, M4 was identified as baicalein-6-O-glucuronide, which was supported by the previous study [11] . Table 1 shows the retention time, ion mass peaks (m/z), and molecular formula of the metabolites, and reaction types. Based on the metabolites analyzed in the cecal contents and urine samples from normal rats, the metabolic pathways of baicalin in them was proposed as shown in Figure 2 . The results indicated that the biotransformation of baicalin included three types of reactions: hydrolysis, methylation and glucuronidation. Wogonin was detected as a metabolite of wogonoside in the cecal contents of nomal rats that received oral wogonoside administration.
Three distinctive metabolites and wogonoside (M1-M4) were detected in the urine samples of normal rats that received wogonoside in contrast to the blank urine. The positive electrospray mass spectrum of M4 showed a [M+H] + ion at m/z 285, which was identified unequivocally as wogonin because it had the same retention time (12.65 min) as an authentic standard and the MS also matched. Metabolite M2 showed an UPLC profile with a retention time at 10.23 min and a protonated molecular ion [M+H] + m/z 461. M2 was recognized as wogonoside by comparison with an authentic standard. Metabolite M1 was detected as a protonated molecular ion [M+H] + at m/z 637 with a retention time of 7.44 min, which was 176 Da higher than the protonated ion of wogonoside. The difference indicated that this metabolite could be the glucuronide conjunction product of wogonoside, wogonin-5-O-glucuronide-7-O-glucuronide, which was consistent with previously published data [15] . Metabolite M2 (m/z 461) eluted at 9.08 min and was an isomer of wogonoside. It produced an ion at m/z 285, which indicated a loss of glucuronic acid (176 Da) and thus confirmed M2 as wogonin-5-O-glucuronide. Table 2 shows the retention time, ion mass peaks (m/z), molecular formula of the metabolites, and reaction types.
According to the above observations, the metabolic pathways of wogonoside in normal rats were proposed as shown in Figure 3 . Hydrolysis and glucuronidation were the two main reaction types of wogonoside in normal rats.
The cecal contents and urine samples of antibiotic-pretreated rats after oral administration of baicalin and wogonoside were analyzed by the UPLC-QTOF/MS method, as with the normal groups. However, only unmetabolized original compounds, but no metabolites, were determined in the cecal contents. Similarly, no metabolite was detected in the urine samples. The mean plasma concentration-time profiles of baicalin and its metabolite, baicalein, after oral administration of 100 mg/kg baicalin to control and antibiotic-treated rats are shown in Figure 4 . The mean plasma concentration-time profiles of wogonoside and its metabolite, wogonin, after oral administration of 50 mg/kg wogonoside are shown in Figure 5 . The pharmacokinetic parameters for oral baicalin and wogonoside are summarized in Table 3 . AUC (area under concentration-time curve) of baicalin in normal rats was 22460.3±9621.9 ng h/mL, C max was 1733.6±756.1 ng/mL and T 1/2 (biological half-life) was
Effects of intestinal microecology on metabolism and pharmacokinetics Natural Product Communications Vol. 12 (4) 2017 511 9.6±1.7 h. In animals with pretreatment antibiotics, the mean plasma concentration-time profiles of baicalin decreased significantly compared with the normal groups. Furthermore, the majority of the parameters for peroral baicalin were considerably affected: AUC of baicalin was reduced to 6115.4±2893.3 ng h/mL, C max (peak concentration) was reduced to 777.3±69.2 ng/mL, and T 1/2 was prolonged to 17.8±1.7 h. The mean plasma concentrationtime profile of baicalein was also significantly affected by antibiotic pretreatment. The AUC ratio of baicalin to baicalein (22460.3±9621.9 vs 4682.6±2735.9 ng h/mL) in normal rats was 4.80:1, while the ratio (6115.4±2893.3 vs 97.0±74.4 ng h/mL) in the antibiotic-treated rats was 63.05:1. There was a significant difference in the AUC ratio of baicalin to baicalein between the normal and antibiotic-treated rats by using Student t test (P<0.01).
The AUC ratio of wogonoside to its metabolite, wogonin, was similar to that of baicalin and baicalein.
The plasma concentration-time curve of baicalin and wogonoside both exhibited a double peak, which indicated that baicalin and wogonoside may have hepatoenteral circulation in vivo [16] . The results clearly indicated that intestinal bacteria can affect the flavonoid glycosides and their intestinal metabolite pharmacokinetics in rats. Therefore, the metabolism conducted by intestinal bacteria is critical to the pharmacological action of flavonoid glycosides.
Studies have been published on the pharmacokinetics and in vitro metabolism of flavanones such as baicalin and wogonoside by intestinal microbiota [17] [18] [19] [20] . However, few publications can clearly demonstrate the potential effects of intestinal microflora on the pharmacokinetics and metabolism of baicalin and wogonoside.
Therefore, in the present study, we investigated the variations in pharmacokinetics and metabolism of baicalin and wogonoside by altering the intestinal microflora in a pseudo-germfree rat model treated with or without antibiotics. Model establishment, drug dosage and times of administration of antibiotics were optimized in our previous study [21] . Pretreatment with oral antibiotics might not be able to remove the bacteria completely in the intestine due to several factors including the environmental exposure to exogenous bacteria and the presence of antibiotic resistant organisms [6] . However, the treatment with antibiotics was strong enough to create a window that allows the differentiation of metabolic and pharmacokinetic patterns produced by intestinal bacteria.
In our present study, there was no hydrolysis and glucuronide product in pseudo-germfree rats receiving oral antibiotics. The corresponding metabolites were analyzed in non-antibiotic-exposed rats. The composition and metabolic activities of the human colonic microbiota were shown to be affected by antibiotics. The number of certain anaerobic and facultative anaerobic organisms decreased significantly after antibiotic treatment. Some of the metabolic activities were also affected by antibiotic treatment [22] . For example, fecal β-glucosidase and α-rhamnosidase activities were significantly higher in normal rats than in pseudo-germ-free rats [6] .
There are various types of anaerobic and facultative anaerobic bacteria present in the intestinal tract. These organisms can produce an even more complex spectrum of metabolic enzymes, such as βglucosidase, α-rhamnosidase, and nitroreductase, which participate in diverse metabolic reactions including glycoside metabolism by intestinal microbiota [23, 24] . Thus, the decrease of glycosidase activity will consequently affect the intestinal bacterial metabolism of the two flavonoids and the further phase II metabolism in vivo. These results were consistent with our earlier findings on intestinal bacterial metabolism in vitro that the metabolism of major flavonoid glycosides in S. baicalensis by fecal microflora from pseudo-germfree rats was remarkably repressed.
After oral administration, baicalin and wogonoside are known to be converted to their aglycon forms, baicalein and wogonin, by βglucosidase of the intestinal microflora and are then absorbed through the gastrointestinal tract [7] [8] [9] . Baicalein and wogonin are immediately metabolized to their glucuronide conjugates in the intestinal epithelium and liver after gastrointestinal absorption [10, 25] . Such phenomena were also confirmed in our study of the metabolites analysis in vivo. The aglycon forms and relevant glucuronides of baicalin and wogonoside were found in the urine and cecal contents of normal rats. However, qualitative differences in the metabolites generated were not noted but pharmacokinetic results revealed changes in the amount of metabolites in pseudogerm-free rats. The plasma concentration-time profiles of baicalin and wogonoside in non-antibiotic-exposed and pseudo-germ-free rats revealed a significant difference in AUC, C max , T max and T 1/2 . In this context, the pharmacokinetic and metabolism differences indicate the effects intestinal bacteria exert on the pharmacokinetics and metabolism of flavonoid glycosides, and further suggest that alterations of gut microflora can affect the pharmacological activities of flavonoid glycosides. In fact, it is generally accepted that dozens of xenobiotics, including drugs, are metabolized by intestinal bacteria, which may modulate the pharmacological and toxicological actions [26] [27] [28] . Many investigations to date have only focused on the metabolism in host tissues, such as the liver. However, the biological activities of these compounds are likely to be affected by various factors related to the condition of gut microflora, including race, food habits, and long-term use of antibiotics. Therefore, effects of intestinal microbiota on pharmacokinetics and metabolism of other xenobiotics need to be explored.
Our results demonstrated that the presence of intestinal bacteria played a critical role in the pharmacokinetics and metabolism of baicalin and wogonoside. The plasma concentration-time profiles and pharmacokinetic parameters of baicalin and wogonoside revealed a significant difference between antibiotics treated pseudogermfree rats and normal rats. In addition, the hydrolysis and glucuronidation products detected in normal rats were not found in antibiotics treated rats. The results indicated that pharmacokinetics, metabolism and pharmacological effects of flavonoid glycosides may be heavily dependent on the status of intestinal bacteria.
Experimental

Materials and reagents:
Baicalein, baicalin, wogonin and wogonoside were purchased from Shanghai Winherb Medical Technology Co., Ltd. Liquiritigenin (purity > 98.0%), internal standard (IS) was obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). HPLC-grade acetonitrile was purchased from Merck (Darmstadt, Germany). Ultrapure water for the LC mobile phase was prepared in-house using a Milli-Q system (Millipore, Bedford, MA, USA). All other chemicals were of analytical grade and used without further purification.
Animals: Specific pathogen-free male Sprague-Dawley rats (7 weeks old, approximately 220-250 g) were purchased from Hercynian Pool-Rubicam Experimental Animals Ltd. Rats were housed in a temperature (25±2℃) and moisture (55±10%) controlled room with access to food and water ad libitum, exposed to a controlled 12 h light/dark cycle. All the animal experiments were approved by Shanghai Jiao Tong University Animal Ethics Committee (Shanghai, China). The animals were randomly divided into 2 groups: the normal group (administered orally deionized water twice per day for 7 days) and the antibiotic treatment groups (administered orally lincomycin hydrochloride 4.8 g/kg twice per day for 7 days) [21] .
Drug administration and sampling:
Baicalin and wogonoside were suspended in 0.5% CMC-Na and orally administered to rats in the antibiotics-pretreated and control groups at a single dose of 100 mg/kg/5 mL and 50 mg/kg/5 mL following an overnight fast, respectively. For pharmacokinetic studies, 0.3 mL blood samples were obtained from the posterior orbital venous plexus to a heparinized tube at 0, 0.167, 0.333, 0.666, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h, and then centrifuged at 10000 rpm for 15 min. The plasma was collected and stored at -80℃. Eight h after oral administration of baicalin and wogonoside, the contents of the cecum were collected from antibiotics-pretreated and normal rats for the analysis of in vivo intestinal metabolites and stored at -80℃ prior to analysis. Urine was collected from the antibiotics-pretreated and control rats after oral administration of baicalin and wogonoside and each animal was housed in a metabolic cage for 24 h.
Sample processing: Plasma samples were thawed to room temperature before analysis. In a 1.5 mL centrifuge tube, an aliquot of 10 μL of the internal standard working solution (5 ng/mL) was added to 100 μL of collected plasma samples, followed by a supplementary addition of 390 μL acetonitrile (4:1, v/v). The tubes were vortexed for 1.0 min. After centrifugation at 14000 rpm for 10 min, the supernatant was evaporated in a 40℃ water bath with a nitrogen blowing instrument. The residue was reconstituted with 100 μL mobile phase. After centrifugation at 14000 rpm for another 5 min, an aliquot of 2 μL supernatant was injected into the LC-MS/MS system. The urine sample were thawed at room temperature and then filtered. Acetonitrile (400 μL) was added to 100 μL of collected urine samples (4:1, v/v). The combined mixture was vortexed for 1 min. After centrifugation at 14000 rpm for 10 min, the supernatant liquid was used for UPLC-QTOF/MS analysis. After being weighed, 100 mg of rat cecal contents were immersed in 400 μL of acetonitrile and vortexed for 1 min. The mixture was centrifuged at 14000 rpm for 10 min and the supernatant liquid was used for UPLC-QTOF/MS analysis.
Preparation of standard solution and calibration standard:
Stock solutions of baicalein, baicalin, wogonin, wogonoside and IS (1 mg/mL) were prepared in acetonitrile. The working solutions at various concentrations were obtained by serial dilutions of the stock solution using acetonitrile. All the solutions were stored at 4℃ until analysis. A standard curve calibration was performed at concentrations of 20, 40, 100, 200, 1000, 2000, 5000, 10000 ng/mL for baicalin, 10, 50, 100, 200, 500, 1000, 2000, 5000 ng/mL for baicalein, 10, 50, 100, 250, 500, 1000, 2500, 5000 ng/mL for wogonoside, and 10, 25, 50, 100, 250, 500, 750, 1000 ng/mL for wogonin, by spiking the working solutions into blank plasma. IS working solutions were prepared with acetonitrile at 5 ng/mL. After the process described in the section Sample Processing, the samples were injected into the LC-MS/MS system. Quality control (QC) samples were prepared at low, medium and high concentrations: 50, 1000, 7500 ng/mL for baicalin, 25, 2000, 4000 ng/mL for baicalein,
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Natural Product Communications Vol. 12 (4) 2017 513 25, 2000 , 4500 ng/mL for wogonoside, and 20, 400, 800 ng/mL for wogonin, respectively. The analytical standards and QC samples were stored at -80°C. .0 for liquiritigenin (IS) with DP of 100 V were monitored, respectively. The MS parameters were as follows: ion spray needle voltage at 5500V and source temperature at 550℃. Following optimization of the setting parameters, the ESI source was operated with the CUR, GS1, and GS2 set at 20, 60, and 40 psi, respectively. The optimized collision energies (CE) for 4 flavonoids and IS was 30 eV. The dwell time was set to 550 ms per transition. MS/MS operating conditions were optimized by infusion of the standard solution (500 ng/mL) of analyte or IS into the ESI source via a syringe pump, respectively.
Apparatus and LC-MS/MS conditions:
Data acquisition was performed using Analyst 1.5.2 software (Applied Biosystems).
Pharmacokinetic parameters:
The total area under the plasma concentration-time curve from time zero to time infinity (AUC) was calculated using the trapezoidal rule-extrapolation method [29] . The area from the last datum point to time infinity was estimated by dividing the last measured plasma concentration by the terminalphase rate constant. Standard methods were used to calculate the following pharmacokinetic parameters using non-compartmental analysis (Kenitica 4.4.1): maximum plasma concentration (Cmax), AUC and terminal half-life (T1/2). The results obtained were expressed as the mean ± S.E. and the statistical significance of the results was analyzed at either P＜0.05 (*) or P＜0.01 (**).
In vivo metabolites analysis: The urine and cecal contents samples were analyzed by a commercially available ACQUITY UPLC system connected to an ACQUITY TQD triple quadrupole mass spectrometer (Waters Corp., Milford, MA, USA) with a conditioned autosampler at 4℃. Data were collected using MassLynx software. The separation was performed on a Syncronis C18 column (100 × 2.1 mm i.d., 1.7 μm; Thermo, USA) with the column temperature set to 35℃. The mobile phase consisted of water-formic acid (100:0.5, v/v, A) and acetonitrile (B) using a gradient elution as follows: 0-1.5 min: 5-10% B, 1.5-8 min: 10-25% B, 8-13 min: 25-45% B, 13-18 min: 45-100% B, 18-21 min: 100% B, 21-24 min: 100-5% B. The flow rate was 0.4 mL/min, and the injection volume was 5 μL. The MS instrument consisted of a Waters Synapt TM QTOF/MS (Waters Corp., Milford, MA, USA). Ionization was performed in the negative electrospray (ESI) mode. Mass range was set at m/z 50-1000 Da with a 0.28 s scan time. The ESI source was operated in negative ionization mode with capillary voltage at 2.0 kV. Source and desolvation temperatures were set at 120 and 350 o C, respectively. Nitrogen was used as desolvation and cone gas with a flow rate of 700 and 50 L/h, respectively. For accurate mass measurement, the data were centroided during acquisition using an external reference (LockSprayTM) comprising a 2 μg/mL solution of leucine-enkephalin (purchased from J&K Chemical Ltd.), which was infused continuously into the ESI source at a rate of 400 μL/min via a syringe pump. The data were processed using MassLynx TM 4.1 software (Waters Corp., Milford, MA, USA).
